Innovative nanocarrier systems enhance siRNA and chemotherapeutic drug co-delivery in breast cancer, suggesting improved treatment options.
Breast cancer's heterogeneity demands innovative therapies. Co-delivery of therapeutics using nanocarriers, especially siRNA combined with other chemotherapeutic drugs, presents a promising avenue. These systems safeguard siRNA, enhance its cellular uptake, and facilitate simultaneous targeting of multiple oncogenic pathways. This multifaceted approach holds potential for superior efficacy and reduced toxicity, addressing the limitations of conventional treatments and paving the way for improved breast cancer therapy.
No takes yet. Share an insight, caveat, or question.
Laxane et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: